Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370093 · ClinicalTrials.gov registry record · Phase 4
Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT04370093 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT04370093, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day, highest approved dose or placebo), WL (10% of body weight, following the established program used in the Diabetes Prevention Program), or Pio+WL. Participants will be evaluated at baseline and after 24 weeks of intervention while on a fixed metabolic diet to exclude the confounding effects of diet and perspiration. The primary endpoint will be change in upH, and multiple additional endpoints (serum, urine, imaging) will be assessed.
Interventions
- DRUG Pioglitazone 45 mg
- BEHAVIORAL Weight Loss
- OTHER Pioglitazone + Weight Loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-10-17 |
| Est. Completion | 2025-05-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04370093
The ClinicalTrials.gov registry entry for NCT04370093 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pioglitazone 45 mg is the first listed.
NCT04370093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04370093 about?
NCT04370093 is a clinical study titled "Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss". The investigators will randomize overweight and obese iuan patients to Pio (45 mg/day, highest approved dose or placebo), WL (10% of body weight, following the established program used in the Diabetes Prevention Program), or Pio+WL. Participants will be evaluated at baseline and after 24 weeks of in...
What is the current status of trial NCT04370093?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 2019-10-17. Estimated completion is 2025-05-28.
What interventions are being tested in trial NCT04370093?
The interventions under investigation include: Pioglitazone 45 mg (DRUG), Weight Loss (BEHAVIORAL), Pioglitazone + Weight Loss (OTHER).
Who is sponsoring clinical trial NCT04370093?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.